Vanda Pharmaceuticals (VNDA) Cash from Financing Activities (2010 - 2026)
Vanda Pharmaceuticals' (VNDA) quarterly Cash from Financing Activities came in at -$776000.0 in Q1 2026, up 41.39% year-on-year from -$548837.6 in Q1 2025, and down 21.25% quarter-over-quarter from -$640000.0 in Q4 2025.
Vanda Pharmaceuticals (VNDA) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Vanda Pharmaceuticals has disclosed Cash from Financing Activities across 15 years of filings, most recently posting -$776000.0 for Q1 2026.
- Cash from Financing Activities for Q1 2026 came in at -$776000.0, up 41.39% year-over-year; the trailing twelve-month figure through Mar 2026 was -$2.4 million (down 59.43% YoY), and the FY2025 annual result was -$2.9 million, down 1774.84% from the prior year.
- Cash from Financing Activities came in at -$776000.0 for Q1 2026 at Vanda Pharmaceuticals, down from -$640000.0 in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $605000.0 in Q4 2022 to a low of -$1.3 million in Q1 2025.
- The 4-year median for Cash from Financing Activities is -$425000.0 (2025), against an average of -$344777.8.
- Across the five-year window, Cash from Financing Activities slumped 312.9% in 2025 and surged 41.39% in 2026, its largest moves.
- Vanda Pharmaceuticals' Cash from Financing Activities stood at $605000.0 in 2022, then tumbled by 125.62% to -$155000.0 in 2024, then plunged by 312.9% to -$640000.0 in 2025, then fell by 21.25% to -$776000.0 in 2026.
- The last three Cash from Financing Activities figures came in at -$776000.0 (Q1 2026), -$640000.0 (Q4 2025), and -$517000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 7.00 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -600,000.00 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 53,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -538.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 85,464.43 |
| 10 | Vanda Pharmaceuticals | 345.46 Mn | 143.15 Mn | 48.56 Mn | -776,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -776,000.00 |
| Mar 31, 2026 | -776,000.00 |
| Dec 31, 2025 | -640,000.00 |
| Dec 31, 2025 | -640,000.00 |
| Sep 30, 2025 | -517,000.00 |
| Sep 30, 2025 | -517,000.00 |
| Jun 30, 2025 | -425,000.00 |
| Jun 30, 2025 | -425,000.00 |
| Mar 31, 2025 | -1.32 Mn |
| Mar 31, 2025 | -1.32 Mn |
| Dec 31, 2024 | -155,000.00 |
| Dec 31, 2024 | -155,000.00 |
| Dec 31, 2022 | 605,000.00 |
| Dec 31, 2022 | 605,000.00 |
| Sep 30, 2022 | 4,000.00 |
| Sep 30, 2022 | 4,000.00 |
| Jun 30, 2022 | 125,000.00 |
| Jun 30, 2022 | 125,000.00 |
| Dec 31, 2021 | 1.04 Mn |
| Dec 31, 2021 | 1.04 Mn |